JACK T STAPLETON, MD
Osteopathic Medicine at Hawkins Dr, Iowa City, IA
License number
Iowa 25543
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Iowa 25543
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
200 Hawkins Dr, Iowa City, IA 52242
Phone
(319) 356-3168
(319) 356-4600 (Fax)
(319) 356-4600 (Fax)
Organization information
See more information about JACK T STAPLETON at bizstanding.comUniversity Of Iowa Hosps CLNCS - Jack T Stapleton MD
200 Hawkins Dr #C606, Iowa City, IA 52242
Categories:
Infectious Disease Physicians & Surgeons
Phone:
(319) 356-1616 (Phone)
Professional information
Protein That Interacts With Lipids And Methods For Treating Hyperlipidemia
US Patent:
2004010, May 27, 2004
Filed:
May 27, 2003
Appl. No.:
10/445724
Inventors:
Jack Stapleton - Iowa City IA, US
Sabina Wuenschmann - Troy VA, US
Sabina Wuenschmann - Troy VA, US
Assignee:
The University of Iowa Research Foundation
International Classification:
C12Q001/70
US Classification:
435/005000
Abstract:
The present invention provides methods of identifying inhibitors of HCV infection. The invention further describes methods of preventing and treating HCV infection in a subject. The invention also describes methods for reducing LDL levels in a subject.
Dr. Jack T Stapleton, Iowa City IA - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
UNIVERSITY OF IOWA HOSPITALS AND CLINICS
200 Hawkins Dr, Iowa City 52242
(319) 356-1616 (Phone), (319) 356-7533 (Fax)
200 Hawkins Dr, Iowa City 52242
(319) 356-3168 (Phone), (319) 356-4600 (Fax)
UNIVERSITY DEPARTMENT-INTERNAL
200 Hawkins Dr STE C33HGH, Iowa City 52242
(800) 777-8442 (Phone), (319) 353-6339 (Fax)
200 Hawkins Dr, Iowa City 52242
(319) 356-1616 (Phone), (319) 356-7533 (Fax)
200 Hawkins Dr, Iowa City 52242
(319) 356-3168 (Phone), (319) 356-4600 (Fax)
UNIVERSITY DEPARTMENT-INTERNAL
200 Hawkins Dr STE C33HGH, Iowa City 52242
(800) 777-8442 (Phone), (319) 353-6339 (Fax)
Certifications:
Infectious Disease, 1986, Internal Medicine, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
UNIVERSITY OF IOWA HOSPITALS AND CLINICS
200 Hawkins Dr, Iowa City 52242
200 Hawkins Dr, Iowa City 52242
UNIVERSITY DEPARTMENT-INTERNAL
200 Hawkins Dr STE C33HGH, Iowa City 52242
University of Iowa Hospital and Clinics
200 Hawkins Dr, Iowa City 52242
200 Hawkins Dr, Iowa City 52242
200 Hawkins Dr, Iowa City 52242
UNIVERSITY DEPARTMENT-INTERNAL
200 Hawkins Dr STE C33HGH, Iowa City 52242
University of Iowa Hospital and Clinics
200 Hawkins Dr, Iowa City 52242
Education:
Medical School
Univ Of Ks Sch Of Med
Graduated: 1980
University of North Carolina Hospitals
Univ Of Ks Sch Of Med
Graduated: 1980
University of North Carolina Hospitals
Full-Length Gb Virus C (Hepatitis G Virus) Rna Transcripts Are Infectious In Primary Cd4 Positive T Cells
US Patent:
6870043, Mar 22, 2005
Filed:
Apr 5, 2001
Appl. No.:
09/828498
Inventors:
Jinhua Xiang - Iowa City IA, US
Sabina Wünschmann - Coralville IA, US
Warren Schmidt - Oxford IA, US
Jack Stapleton - Iowa City IA, US
Sabina Wünschmann - Coralville IA, US
Warren Schmidt - Oxford IA, US
Jack Stapleton - Iowa City IA, US
Assignee:
The University of Iowa Research Foundation - Iowa City IA
International Classification:
C07H021/04
US Classification:
536 2372, 4241891, 4242181, 435 691, 4353201, 536 231
Abstract:
GB virus C (GBV-C or hepatitis G virus) is a recently described flavivirus that frequently leads to chronic viremia in humans. Although associated with acute post-transfusion hepatitis, it is not clear if GBV-C is pathogenic for humans. A full-length cDNA was constructed from the plasma of a person with chronic GBV-C viremia. Peripheral blood mononuclear cells (PBMCs) transfected with full-length RNA transcripts from this GBV-C clone resulted in viral replication, demonstrating an isolated infectious GBV-C nucleic acid molecule. In addition to composition involving an isolated infectious GBV-C nucleic acid molecule, the present invention concerns methods of inhibiting and treating HIV infections.
Novel Antiviral Acitivities Of Primate Theta Defensins And Mammalian Cathelicidins
US Patent:
2004008, May 6, 2004
Filed:
Nov 25, 2003
Appl. No.:
10/721839
Inventors:
Wendy Maury - Coralville IA, US
Jack Stapleton - Iowa City IA, US
Richard Roller - Coralville IA, US
Mark Stinski - North Liberty IA, US
Paul McCray - Iowa City IA, US
Brian Tack - Iowa City IA, US
Jack Stapleton - Iowa City IA, US
Richard Roller - Coralville IA, US
Mark Stinski - North Liberty IA, US
Paul McCray - Iowa City IA, US
Brian Tack - Iowa City IA, US
Assignee:
The University of Iowa Research Foundation
International Classification:
A61K045/00, A61K047/00
US Classification:
424/278100
Abstract:
The present invention relates to the use of anti-viral peptides in the inhibition and treatment of viral infections, in particular infections caused by enveloped viruses. These anti-viral peptides, some natural and others artificial, adopt either amphiphilic alpha-helical or a theta structure where the homodimeric or heterodirner peptides are joined by both cysteine bonds and circularization of the peptides. These agents may be used alone or in combination with more traditional anti-viral pharmaceuticals.
Recombianant Hepatitis A Virus
US Patent:
5294548, Mar 15, 1994
Filed:
Jul 3, 1991
Appl. No.:
7/725178
Inventors:
James H. McLinden - Mishawaka IN
Elliot D. Rosen - South Bend IN
Patricia L. Winokur - Chevy Chase MD
Jack T. Stapleton - Iowa City IA
Elliot D. Rosen - South Bend IN
Patricia L. Winokur - Chevy Chase MD
Jack T. Stapleton - Iowa City IA
Assignee:
American Biogenetic Sciences, Inc - Copiague NY
University of Iowa Research Foundation - Iowa City IA
University of Iowa Research Foundation - Iowa City IA
International Classification:
A61K 3929, C12N 701, C12N 1586
US Classification:
4352351
Abstract:
The present invention is directed to genetically engineered expression systems which encode a recombinant Hepatitis A virus (HAV) proteins capable of forming capsid particles. By way of example baculovirus vectors were utilized in order to express recombinant HAV proteins. The recombinant baculoviruses of the invention are formed by replacing regions of the polyhedrin structural gene coding sequences with HAV DNA by recombinant DNA techniques. Additionally, the polyhedrin transcriptional initiation site is altered in these recombinant baculoviruses such that only HAV proteins and not polyhedrin protein sequences are expressed from the polyhedrin promoter. The recombinant HAV capsid particles produced in accordance with the present invention can be particularly useful as vaccines.
Flavivirus Ns5A Proteins For The Treatment Of Hiv
US Patent:
7951531, May 31, 2011
Filed:
Feb 1, 2006
Appl. No.:
11/345662
Inventors:
Jack T. Stapleton - Iowa City IA, US
Jinhua Xiang - Iowa City IA, US
Qing Chang - Iowa City IA, US
James McLinden - Coralville IA, US
Jinhua Xiang - Iowa City IA, US
Qing Chang - Iowa City IA, US
James McLinden - Coralville IA, US
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
C12Q 1/70, A61K 39/21, A61K 39/29
US Classification:
435 5, 4242081, 4242281
Abstract:
GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a-GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.
Hepatitis C Virus Fc-Binding Function
US Patent:
5846735, Dec 8, 1998
Filed:
Apr 18, 1996
Appl. No.:
8/634545
Inventors:
Jack T. Stapleton - Iowa City IA
Jian-Qiu Han - Shanghai, CN
Douglas LaBrecque - Iowa City IA
Warren N. Schmidt - Iowa City IA
Jian-Qiu Han - Shanghai, CN
Douglas LaBrecque - Iowa City IA
Warren N. Schmidt - Iowa City IA
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
G01N 3353, G01N 33576, C07K 1600, C07K 14735
US Classification:
435 71
Abstract:
The present invention involves the detection and purification of Hepatitis C Virus (HCV). More particularly, the invention involves the exploitation of a newly discovered Fc-binding function in HCV to capture HCV from infected samples. This permits greatly simplified methods of diagnosis, improved methods of treatment and, in addition, the first opportunity to purify significant quantities of HCV.
Flavivirus Ns5A Proteins For The Treatment Of Hiv
US Patent:
8268778, Sep 18, 2012
Filed:
Mar 20, 2008
Appl. No.:
12/532064
Inventors:
James McLinden - Coralville IA, US
Jinhua Xiang - Iowa City IA, US
Jack T. Stapleton - Iowa City IA, US
Jinhua Xiang - Iowa City IA, US
Jack T. Stapleton - Iowa City IA, US
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
A01N 37/18, A61K 38/00, A61P 31/18
US Classification:
514 38, 514 39
Abstract:
GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a -GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.
Gb Virus C (Hepatitis G Virus) For The Treatment Of Hiv
US Patent:
2009001, Jan 8, 2009
Filed:
Jul 24, 2008
Appl. No.:
12/179399
Inventors:
JACK T. STAPLETON - Iowa City IA, US
Jinhua Xiang - Iowa City IA, US
Donna Klinzman - Coralville IA, US
James H. McLinden - Coralville IA, US
Jinhua Xiang - Iowa City IA, US
Donna Klinzman - Coralville IA, US
James H. McLinden - Coralville IA, US
International Classification:
C07K 16/08, A61K 39/395, A61K 31/7072, A61K 31/711, A61K 39/29
US Classification:
4241331, 5303871, 53038822, 5303873, 4241591, 4241471, 514 51, 4242181, 4241891, 435 696
Abstract:
GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
Gb Virus C And Methods Of Treating Viral Infections
US Patent:
7291723, Nov 6, 2007
Filed:
Oct 24, 2003
Appl. No.:
10/693258
Inventors:
Jack T. Stapleton - Iowa City IA, US
Jinhua Xiang - Iowa City IA, US
Sarah George - St. Louis MO, US
Jinhua Xiang - Iowa City IA, US
Sarah George - St. Louis MO, US
Assignee:
University of Iowa Research Foundation - Iowa City IA
International Classification:
C07H 21/04
US Classification:
536 2372, 4241891, 4242181, 435 691, 4353201, 536 231
Abstract:
The present application provides GB virus C sequences (GBV-C or hepatitis G virus) and methods of using the sequences.